Explaining fatigue in ANCA-associated vasculitis

Explaining fatigue in ANCA-associated vasculitis

Show other versions (1)

Detalles Bibliográficos
Main Authors:	Basu, N, McClean, A, Harper, L, Amft, E, Dhaun, N, Luqmani, R, Little, M, Jayne, D, Flossmann, O, McLaren, J, Kumar, V, Erwig, L, Reid, D, Macfarlane, G, Jones, G
Formato:	Journal article
Publicado:	2013

Títulos similares

Explaining fatigue in ANCA-associated vasculitis.
por: Basu, N, et al.
Publicado: (2013)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
por: Basu, N, et al.
Publicado: (2012)

The characterisation and determinants of quality of life in ANCA associated vasculitis
por: Basu, N, et al.
Publicado: (2014)

The characterisation and determinants of quality of life in ANCA associated vasculitis.
por: Basu, N, et al.
Publicado: (2014)

Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV).
por: Basu, N, et al.
Publicado: (2012)

Markers for work disability in ANCA-associated vasculitis
por: Basu, N, et al.
Publicado: (2013)

Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.
por: Basu, N, et al.
Publicado: (2014)

Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV)
por: Salisbury, E, et al.
Publicado: (2003)

INCIDENCE OF NON-FATAL CLINICAL CORONARY EVENTS IN PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
por: Salisbury, E, et al.
Publicado: (2003)

CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV)
por: Salisbury, E, et al.
Publicado: (2004)

Cardiovascular outcomes in ANCA associated vasculitis
por: Mukhtyar, C, et al.
Publicado: (2008)

Incidence of non-fatal clinical coronary events in primary ANCA-associated systemic vasculitis (aasv)
por: Salisbury, E, et al.
Publicado: (2003)

DEVELOPMENT OF DIAGNOSTIC CRITERIA FOR PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
por: McLaren, J, et al.
Publicado: (2003)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
por: Suppiah, R, et al.
Publicado: (2011)

Long-term survival of ANCA-associated vasculitis
por: Flossmann, O, et al.
Publicado: (2009)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
por: Luqmani, R, et al.
Publicado: (2007)

DIAGNOSTIC CRITERIA FOR ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV) IN PATIENTS PRESENTING WITH ACUTE PULMONARY AND/OR RENAL DISEASE
por: McLaren, J, et al.
Publicado: (2004)

Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting
por: McLaren, J, et al.
Publicado: (2001)

Long-term patient survival in ANCA-associated vasculitis
por: Flossmann, O, et al.
Publicado: (2011)

Long-term patient survival in ANCA-associated vasculitis.
por: Flossmann, O, et al.
Publicado: (2011)

Diagnosis and management of ANCA associated vasculitis.
por: Berden, A, et al.
Publicado: (2012)

Long-term patient survival in ANCA-associated vasculitis.
por: Flossmann, O, et al.
Publicado: (2011)

A four year analysis of variation in use of the anti-neutrophil cytoplasmic antibody (ANCA) test as a screening tool for ANCA-associated systemic vasculitis (AAV) in a teaching hospital.
por: McLaren, J, et al.
Publicado: (2000)

TREATMENT-RELATED DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
por: Robson, J, et al.
Publicado: (2013)

Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials.
por: Robson, J, et al.
Publicado: (2015)

Damage in the ANCA-associated vasculitides: Long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials
por: Robson, J, et al.
Publicado: (2015)

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
por: Lapraik, C, et al.
Publicado: (2007)

BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
por: Ntatsaki, E, et al.
Publicado: (2014)

Predictors of renal involvement in ANCA associated vasculitis
por: Kronbichler, A, et al.
Publicado: (2018)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
por: Suppiah, R, et al.
Publicado: (2011)

Damage assessment in ANCA-associated vasculitis.
por: Bhamra, K, et al.
Publicado: (2012)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
por: Suppiah, R, et al.
Publicado: (2011)

FACTORS ASSOCIATED WITH LONG-TERM DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF COHORTS FROM THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
por: Robson, J, et al.
Publicado: (2013)

Maintenance of clinical remission in ANCA-associated vasculitis.
por: Luqmani, R
Publicado: (2013)

Outcome measures in ANCA-associated vasculitis.
por: Suppiah, R, et al.
Publicado: (2010)

The UK & Ireland Vasculitis Registry (UKIVAS): Cross-sectional data on the first 2290 Patients with anti-neutrophil cytoplasm (ANCA) associated vasculitis (AAV)
por: Luqmani, R, et al.
Publicado: (2017)

Comparison of disease activity measures for ANCA-associated vasculitis.
por: Merkel, P, et al.
Publicado: (2004)

Diagnosis and assessment of systemic vasculitis.
por: McLaren, J, et al.
Publicado: (2002)

A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (Cycazarem).
por: Luqmani, R, et al.
Publicado: (1999)

Opinion: Maintenance of clinical remission in ANCA-associated vasculitis
por: Luqmani, R
Publicado: (2013)